Merck Buys Schering-Plough -- and Time
Executive Summary
Merck's acquisition of Schering-Plough is all about buying breathing room, relief from what looks to be a 4-year, 50% earnings decline as key products go generic. Moreover, the relief comes relatively inexpensively (unless J&J steps in with a counteroffer), a fact that reflects Schering's lack of strategic options. In this interview, Merck's R&D boss Peter Kim and chief strategist, Mervyn Turner, explain the key pipeline and marketing complementarities and cost-cutting possibilities which prompted the deal -- and how they plan to integrate the two businesses.
You may also be interested in...
At Merck, Business Development As Usual?
Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.
At Merck, Business Development As Usual?
Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty